Retrospective Sample Collection – Biomarker Discovery to Help Rescue your Drug
Sample Access and Profiling for Biomarker Discovery to Help Rescue or Reposition your Drug
With personalised medicine becoming more commonly accepted, an increasing number of drugs in development have a biomarker strategy. In situations where a drug has not performed as well as hoped, a biomarker strategy could potentially rescue the drug or increase market uptake through the use of a companion diagnostic.
Almac have developed a service to enable biomarker studies to be carried out retrospectively in trials where there was not one in place from the start.
This service includes obtaining ethical approval and corresponding consent, identification of clinical information for patients in partnership with investigators, contractual arrangements, sample sourcing and providing full logistical and regulatory oversight of sample preparation, shipping, receipt and biobanking.
Almac have a team of highly experienced experts that work exclusively in the delivery of this service, that have:
- Established workflows for projects of this type
- Expertise and experience of ethical submission and regulatory requirements in a range of countries and institutions
- A prepared bank of template documentation for this type of study
- Experience of working with large number of recruiting sites worldwide
- Relationships with many different investigators and background staff in recruiting centres
- Extensive experience in contractual arrangements for sample access and shipping worldwide
- Global capabilities to expedite the process of clinical site participation and sample access
- Experts in sample preparation, packaging and shipping
- Experience in study design and delivery of large research studies which involve a wide range of downstream genomic and proteomic assays that impact upstream sample selection and preparation
- Specialist knowledge and vast experience of working in a range of oncology indications
In this webinar, Almacs head of project management Dr Peter Kerr, along with Michael Sloan, VP of Business Development, and Kinga Wojciechowska, lead project manager for Ethics and Tissue Collection, give an overview of the service. The talk highlights the reasons for the development of the service and give some details on the potential benefits to biopharma. The details of the service are explained and a case study is used to elucidate the process.
Speakers:
- Dr. Peter Kerr, Head of Project Management & Product Development, Almac Diagnostic Services
- Michael Sloan, Vice President, Business Development, Almac Diagnostic Services
- Kinga Wojciechowska, Project Manager – Ethics/Tissue Collection, Almac Diagnostic Services
Please complete the form below to view webinar: